Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06811272 · ClinicalTrials.gov registry record · Phase 2
Outpatient Epcoritamab as 2L in NTE R/R DLBCL
A Phase 2 study of Relapsed Large B-cell Lymphoma and Refractory Large B-cell Lymphoma, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT06811272: Recruiting Phase 2 study of Relapsed Large B-cell Lymphoma and Refractory Large B-cell Lymphoma, sponsored by Massachusetts General Hospital.
NCT06811272 is a Phase 2 study of Relapsed Large B-cell Lymphoma and Refractory Large B-cell Lymphoma that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06811272, a Phase 2 study of Relapsed Large B-cell Lymphoma and Refractory Large B-cell Lymphoma, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.
Primary Outcome
The CRR is defined as the proportion of subjects achieving an objective response of complete response (CR) according to the Lugano Classification, prior to start of another non-study anticancer therapy. CRR is based on the best overall response. CRR will be reported as a proportion, exact binomial confidence interval, and assessed using an exact binomial test.
Conditions Studied
Interventions
- DRUG Epcoritamab
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Newton-Wellesley Hospital - Newton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-06-05 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 2 |
What NCT06811272 shows while recruiting
NCT06811272 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Relapsed Large B-cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Epcoritamab is the first listed.
NCT06811272 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06811272 about?
NCT06811272 is a clinical study titled "Outpatient Epcoritamab as 2L in NTE R/R DLBCL". The purpose of this study is to measure the efficacy of the study drug, epcoritamab, in participants with relapsed/refractory large B-cell lymphoma.
What is the current status of trial NCT06811272?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-06-05. Estimated completion is 2028-10-01.
What conditions does trial NCT06811272 study?
This clinical trial studies the following conditions: Relapsed Large B-cell Lymphoma, Refractory Large B-cell Lymphoma.
What interventions are being tested in trial NCT06811272?
The interventions under investigation include: Epcoritamab (DRUG).
Who is sponsoring clinical trial NCT06811272?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06811272 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06811272's enrollment target sits among peer trials
30 1582nd of 2000 higher than 333 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI